Intelligence · Patents
Patents expiring in 2039
Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.
- Patents
- 1,782
Quick answer
1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10272093
Use of H3K9me3 modulation for enhancing cognitive function
granted -
US 10272075
Method and composition for treating an alpha adrenoceptor-mediated condition
granted -
US 10272158
Compounds for treating biofilm infection
granted -
US 10272184
Hydrogel membrane for adhesion prevention
granted -
US 10273292
Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
granted -
US 10273281
CD80 extracellular domain polypeptides and their use in cancer treatment
granted -
US 10273333
Substituted polyesters by thiol-ene modification: rapid diversification for therapeutic protein stabilization
granted -
US 10273477
Therapeutic compositions
granted -
US 10273233
Inhibitors of influenza viruses replication
granted -
US 10273245
1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
granted -
US 10273244
Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
granted -
US 10273288
Neutralizing antibodies to Ebola virus glycoprotein and their use
granted -
US 10272163
Factor VIII mutation repair and tolerance induction
granted -
US 10273225
Pyrazines as modulators of GPR6
granted -
US 10273291
Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
granted -
US 10272132
Peptide and peptidomimetic inhibitors
granted -
US 10273228
Hepatitis B viral assembly effectors
granted -
US 10272113
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 10272099
Tumor-selective combination therapy
granted -
US 10272069
Methods of treating muscular dystrophy
granted -
US 10272137
Compositions and methods relating to myomaker-induced muscle cell fusion
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted -
US 10273299
Antibodies to tumor endothelial marker 8
granted -
US 10273274
Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5
granted -
US 10273218
BCL-3 inhibitors
granted -
US 10272146
Purified plasmodium and vaccine compositions
granted -
US 10272046
Pharmaceutical composition and administrations thereof
granted -
US 10272607
Manufacturing of small film strips
granted -
US 10272139
Process, tube and device for the preparation of wound healant composition
granted -
US 10272076
Methods for the administration of iloperidone
granted -
US 10272074
Inhibitors of glucocorticoid receptor translocation
granted -
US 10272173
Radioactive bone cement
granted -
US 10273189
Zirconia composition, zirconia pre-sintered body and zirconia sintered body, and dental product
granted -
US 10272037
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 10272051
Method to treat atopic dermatitis
granted -
US 10272039
Topical sodium nitrite formulation
granted -
US 10272034
Auris formulations for treating otic diseases and conditions
granted -
US 10272055
Therapeutic compounds and methods
granted -
US 10273482
dsRNA for treating viral infection
granted -
US 10280414
Stabilized α-galactosidase and uses thereof
granted -
US 10280160
Phthalazinone compounds and methods for the treatment of cystic fibrosis
granted -
US 10279038
Agonist antibodies that bind human CD137 and uses thereof
granted -
US 10280422
MiR-92 inhibitors and uses thereof
granted -
US 10278986
Antibody-siRNA conjugates and uses therefor
granted -
US 10278372
Genetically modified cells, tissues, and organs for treating disease
granted -
US 10278957
Opioid agonist peptides and uses thereof
granted -
US 10280158
Immune adjustment compound, use thereof and pharmaceutical composition comprising same
granted -
US 10278977
Methods for treating hypersomnolence
granted
Frequently asked questions
How many pharma patents expire in 2039?
1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.